| Ticker |
IBRX
|
| CIK | 0001326110 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121 |
| Website | immunitybio.com |
| Phone | (844) 696-5235 |
| CEO | Richard Adcock |
| Employees | 590 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder CancerWe recently compiled a list of 11 Best Future Stocks to Buy Now. ImmunityBio, Inc. stands eleventh on our list. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body’s natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already been approved […] ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional InvestorsCULVER CITY, Calif., July 25, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory UpdatesCULVER CITY, Calif., July 25, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced preliminary financial results for the fiscal quarter ended June 30, 2025, and clinical progress across its pipeline. ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory AgencyImmunityBio, Inc. (NASDAQ:IBRX) is one of the Best American Penny Stocks to Buy According to Analysts. On July 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced that the UK’s Medicines and Healthcare products Regulatory Agency has approved ANKTIVA with Bacillus Calmette-Guérin for treating certain bladder cancer patients. This is significant as it marks the first approval for the company […] Exploring 3 High Growth Tech Stocks In The US MarketThe U.S. market is currently experiencing a mix of volatility and optimism, with investor sentiment being influenced by renewed tariff threats and record highs in major indices like the S&P 500 and Nasdaq Composite. In this environment, identifying high growth tech stocks requires careful consideration of their potential to thrive amidst economic uncertainties, driven by innovation and strong market positioning. |
